A Phase Ib/II Study of GDC-0068 or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Trial Profile

A Phase Ib/II Study of GDC-0068 or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Apitolisib (Primary) ; Ipatasertib (Primary) ; Abiraterone acetate; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms A. MARTIN study
  • Sponsors Genentech
  • Most Recent Events

    • 22 Aug 2017 Planned End Date changed from 30 Jun 2017 to 29 Jun 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 20 Mar 2017 Planned End Date changed from 1 Nov 2015 to 30 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top